ERBB2 and breast cancer: HCL of MAPK-RTK pathway proteins distinguished three sample groups separating n = 19 HR+ BC-PDMs with overall decreased protein abundances from n = 19 TNBC, HER2 + and HR+ BC-PDMs with elevated expression levels (Fig. 5B).